No abstract

Background:Syringoma is a benign adnexal tumor derived from intraepidermal eccrine duct.Aim:The aim of the study is to report the experience concerning syringoma by reviewing the clinical and histopathologic features of a series of 34 histologically diagnosed syringoma patients observed over a period of six years.Materials and Methods:Thirty-four patients were sorted into two groups, localized and generalized syringoma, according to the Friedman and Butler classification. Different histopathologic findings were recorded in specially designed questionnaires for further analysis.Results:Ninety-seven percent of the patients were females with the mean age of 27.6 years. The mean duration of the lesions before the presentations was six years. The diagnosis of syringoma was only considered in 23 patients (67.6%) and was the initial diagnosis in only 13 (38.2%) patients. All histological findings were seen more common in our cases. in comparison to the documented cases in the literature. Clear cell change of epithelial eccrine cells was 85.2% and there was no difference in the histopathological findings in the two groups. Our patients with generalized syringoma (GS) had a considerable lower age of onset than the ones with localized syringoma (LS) (P = 0.027).Conclusion:Our patients with generalized syringoma were younger than the ones with localized syringoma. Distribution of the generalized syringoma was mainly in the chest and neck followed by the forearms whereas localized syringoma was mostly confined to the face, axilla and genitalia. There were also some conditions associated with our cases including sarcoidosis, calcinosis cutis and basal cell carcinoma.

Background: 18 F-Fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) and 18 F-florbetapir PET are approved neuroimaging biomarkers for the Alzheimer's disease (AD) and mild cognitive impairment (MCI).Objectives: This study aims to compare the efficacy of 18 F-FDG and 18 F-florbetapir PET at evaluating the cognitive performance of patients with AD, MCI, and normal controls (NC). Methods: 63 subjects (36 male/27 female, mean age = 68.3) including 19 AD, 23 MCI, and 21 NC underwent 18 F-FDG and 18 F-florbetapir PET imaging. A global quantification approach was applied on supra-tentorial, frontal, parieto-occipital, temporal, and cerebellar brain regions by calculating the global SUVmean ratios (GSUVr) as the weighted average of all regional SUVmean. 18 F-FDG and 18 F-florbetapir GSUVr of each region were subsequently correlated with the Mini-Mental State Examination (MMSE). Results: Subjects were studied in five categories as NC, MCI patients, AD patients, MCI and AD patients grouped together (MCI/AD), and a group including all the subjects (NC/MCI/AD). Both 18 F-FDG and 18 F-florbetapir could successfully detect subjects with dementia (p < 0.001). Studied in all regions and groups, the correlation analysis of 18 F-FDG GSUVr with MMSE scores was significant in more regions and groups compared to that of 18 F-florbetapir. We also demonstrated that the correlation of 18 F-FDG GSUVr with MMSE is stronger than that of 18 F-florbetapir in the supra-tentorial and temporal regions. Conclusions: This study reveals how 18 F-FDG-PET global quantification is a superior indicator of cognitive performance in AD and MCI patients compared to 18 F-florbetapir PET. Accordingly, we still recommend 18 F-FDG-PET over amyloid imaging in the evaluation for AD and MCI.

No abstract